AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

The UK is seeing an overall improvement in its desirability as a clinical trials location, but it still has ground to make up.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.